All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Biomarkers in immunoglobulin light chain amyloidosis

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R4R" target="_blank" >RIV/61988987:17110/17:A1801R4R - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/17:00098262 RIV/00216208:11110/17:10365703 RIV/65269705:_____/17:00067299 RIV/00843989:_____/17:E0106564 and 2 more

  • Result on the web

    <a href="http://dx.doi.org/10.14735/amko20172S60" target="_blank" >http://dx.doi.org/10.14735/amko20172S60</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.14735/amko20172S60" target="_blank" >10.14735/amko20172S60</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Biomarkers in immunoglobulin light chain amyloidosis

  • Original language description

    Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction. As amyloid depositing in target organs is irreversible, there is a big effort to identify bio marker that could help to distinguish ALA from other monoclonal gammopathies in the early stages of disease, when amyloid deposits are not fatal yet. High throughput technologies bring new opportunities to modern cancer research as they enable to study disease within its complexity. Sophisticated methods such as next generation sequencing, gene expression profiling and circulating microRNA profiling are new approaches to study aberrant plasma cells from patients with light chain amyloidosis and related diseases. While generally known mutation in multiple myeloma patients (KRAS, NRAS, MYC, TP53) were not found in ALA, number of mutated genes is comparable. Transcriptome of ALA patients proves to be more similar to monoclonal gammopathy of undetermined significance patients, moreover level of circulating microRNA, that are known to correlate with heart damage, is increased in ALA patients, where heart damage in ALA typical symptom.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Klinicka Onkologie

  • ISSN

    0862-495X

  • e-ISSN

  • Volume of the periodical

    30

  • Issue of the periodical within the volume

    13. 7. 2017

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    8

  • Pages from-to

    60-67

  • UT code for WoS article

  • EID of the result in the Scopus database

    2-s2.0-85029484418